China’s Low-Cost Push to Rival High-Cost Medicines
China; pharmaceuticals; low-cost drugs; life-saving medicine
Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors
Odyssey Therapeutics; Nia Tatsis; Board of Directors; Vertex Pharmaceuticals; RIPK2 scaffolding inhibitor; autoimmune diseases; biopharmaceuticals; regulatory affairs; quality assurance
Evommune Files for IPO to Fund Phase 2 Trials of Autoimmune Drug Candidates
Evommune; IPO; Phase 2 trials; autoimmune drugs; EVO756; EVO301; chronic inflammatory diseases; biotech funding; New York Stock Exchange; Series C financing
Eli Lilly Commits Over $1 Billion to Expand India Manufacturing Footprint
Eli Lilly; India; manufacturing; investment; contract manufacturing; pharmaceuticals; Hyderabad
UK Proposes Raising Payment Scheme for Branded Medicines to Nearly 25% Amid Industry Pushback
UK medicine pricing; NHS spending; statutory scheme; drugmakers; payment percentage; pharmaceutical rebates; industry response; consultation 2025
Eli Lilly to Invest Over $1 Billion to Expand Manufacturing Footprint in India
Eli Lilly; India; manufacturing expansion; contract manufacturing; Hyderabad; pharmaceuticals; obesity; diabetes; Alzheimer’s; cancer; autoimmune
US Government Backs In Vivo Cell Therapy Startup with Major Funding
federal funding; in vivo cell therapy; startup; immunoVec; US government
AI is Transforming Drug Safety—But Governance Sets Essential Guardrails
artificial intelligence; drug safety; pharmacovigilance; adverse drug events; regulatory governance; FDA; EMEA; AI guardrails; data integrity; bias; patient safety
Ferring Pharmaceuticals to Cut 500 Jobs in Global Restructuring Effort
Ferring Pharmaceuticals; Layoffs; Global Restructuring